title: Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF.
abstract: The influence of various patient and disease-related parameters on survival (S) and disease-free survival (DFS) in 217 node positive primary breast cancer patients treated with surgery followed by adjuvant i.v. cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) was evaluated by univariate and multivariate analyses. Five year actuarial S and DFS were 73.3% and 54.8%, respectively. Univariate analysis revealed that patient age, number of involved axillary nodes and ER status had a significant impact on both S and DFS. PgR positive tumors had improved DFS but no S difference was observed. Menopausal status predicted S but not DFS. Primary tumor size and CMF-induced amenorrhea did not predict disease outcome. Multivariate analysis demonstrated that only degree of nodal involvement and PgR status had independent significant impact on prognosis. Both S and DFS are significantly influenced by the number of involved nodes, whereas improved DFS but not S was evident in patients with PgR positive tumors.
authors.affiliation: Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Campora
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: D
authors.initials: D
authors.lastname: Amoroso
authors.forename: G F
authors.initials: GF
authors.lastname: Bertelli
authors.forename: M
authors.initials: M
authors.lastname: Venturini
authors.forename: E
authors.initials: E
authors.lastname: Baldini
authors.forename: I
authors.initials: I
authors.lastname: Brunetti
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: P
authors.initials: P
authors.lastname: Conte
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate